CapsoVision Reports First Quarter 2026 Financial Results

▤ Summary

CapsoVision reported first quarter 2026 revenue of $2.8 million, essentially flat year-over-year. Gross profit fell to $1.3 million and gross margin declined to 48% due in part to changes in U.S. trade policies and tariffs, while operating expenses rose to $8.4 million driven by CMOS sensor development with Canon and clinical trial work. The company completed a $14 million private placement on March 16, 2026 and held $17.9 million in cash at quarter end. Product and regulatory progress includes an AI-assisted reading feature for CapsoCam Plus anticipated for FDA clearance mid-year, a planned 510(k) submission for second-generation CapsoCam Colon in Q3 2026, and initial patient enrollment in a pancreatic cancer study for CapsoCam UGI.

▦ Linked Companies